ANGO - アンジオダイナミクス (AngioDynamics Inc.)

ANGOのニュース

   AngioDynamics, Inc. 2023 Q3 - Results - Earnings Call Presentation (NASDAQ:ANGO)  2023/03/30 18:10:03 Seeking Alpha
The following slide deck was published by AngioDynamics, Inc.
   AngioDynamics Inc. (ANGO) Q3 2023 Earnings Call Transcript | AlphaStreet  2023/03/30 16:39:31 AlphaStreet
AngioDynamics Inc. (NASDAQ: ANGO) Q3 2023 earnings call dated Mar. 30, 2023
   AngioDynamics, Inc. (ANGO) Q3 2023 Earnings Call Transcript  2023/03/30 14:59:04 Seeking Alpha
AngioDynamics, Inc. (NASDAQ:NASDAQ:ANGO) Q3 2023 Earnings Call Transcript March 30, 2023 8:00 AM ETCompany ParticipantsJim Clemmer - CEOSteve Trowbridge - CFOConference Call…
   SCYNEXIS, Palisade top healthcare gainers; AngioDynamics, Avidity lead losers'' pack  2023/03/30 14:02:34 Seeking Alpha
SCYNEXIS (SCYX) +61%. Palisade Bio (PALI) +33%. AngioDynamics (ANGO) -28%. Avidity Biosciences (RNA) -21%.
   ANGO Earnings: AngioDynamics reports loss for Q3; revenue up 9% | AlphaStreet  2023/03/30 12:53:45 AlphaStreet
AngioDynamics Inc. (NASDAQ: ANGO) on Thursday reported a wider loss for the third quarter of 2023 when the medical device maker''s revenues increased by 9%. The company also provided guidance for fiscal 2023. AngioDynamics reported an adjusted net loss of $0.03 per share for the third quarter, compared to earnings of $0.03 per share in […]
   A Mostly Clean Quarter Drives A Better Valuation For AngioDynamics  2023/01/06 21:21:49 Seeking Alpha
AngioDynamics posted a pretty clean fiscal Q2 that was a little better than the sell-side expected. Click here to read our analysis of ANGO stock.
   AngioDynamics Shares Up 11% on 2Q Sales Gain  2023/01/05 16:46:00 MarketWatch
By Kathryn Hardison Shares of AngioDynamics Inc. increased 11% to $15.07 on Thursday after the company reported a boost to second-quarter sales. Shares…
   AngioDynamics, Inc. 2023 Q2 - Results - Earnings Call Presentation (NASDAQ:ANGO)  2023/01/05 16:18:19 Seeking Alpha
The following slide deck was published by AngioDynamics, Inc.
   AngioDynamics, Inc. (ANGO) Q2 2023 Earnings Call Transcript  2023/01/05 16:17:02 Seeking Alpha
AngioDynamics, Inc. (NASDAQ:NASDAQ:ANGO) Q2 2023 Earnings Conference Call January 05, 2023, 08:00 AM ET Company Participants Jim Clemmer - President and CEO Steve Trowbridge - Executive…
   AngioDynamics Non-GAAP EPS of $0.01 beats by $0.02, revenue of $85.4M beats by $1.02M, reaffirms fiscal year 2023 outlook  2023/01/05 12:20:17 Seeking Alpha
AngioDynamics press release (ANGO): Q2 Non-GAAP EPS of $0.01 beats by $0.02.Revenue of $85.4M (+9.1% Y/Y) beats by $1.02M.Fiscal Year 2023 Financial Guidance: Management is…
   Interventional Radiology Devices Market to See Huge Growth by 2027 : Guerbet, Medtronic, Biotronik  2022/08/08 18:25:00 SBWire
New Jersey, USA -- ( SBWIRE ) -- 08/08/2022 -- The latest study released on the Global Interventional Radiology Devices Market by AMA Research evaluates market size, trend, and forecast to 2027. The Interventional Radiology Devices market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors. Key Players in This Report Include: Abbott (United States), B. Braun (Germany), Boston Scientific (United States), Koninklijke Philips (Netherlands), Cardinal Health (United States), Medtronic (Ireland), Alvimedica (Turkey), Guerbet (France), Angiodynamics (United States), Balton (Poland) and Brosmed Medical (China). Additionally, following companies can also be profiled that are part of our coverage like Biosensors (Switzerland), Biotronik (Germany), Cook Medical (United States) and Endocor (Germany) Download Sample Report PDF (Including Full TOC, Table & Figures) @ https://www.advancemarketanalytics.com/sample-report/78326-global-interventional-radiology-devices-market Definition: Image-guided surgery seems to be what interventional radiology is all about.
   AngioDynamics to Present at the Canaccord Genuity Growth Conference  2022/08/03 20:01:00 Business Wire
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference at 2:00 p.m. ET on Wednesday, August 10, 2022. A live webcast
   AngioDynamics: Growth Is Encouraging, But Margins Still A Work In Progress (NASDAQ:ANGO)  2022/07/14 03:32:08 Seeking Alpha
AngioDynamics posted better sales growth in FQ4''22 as elective procedure counts continue to rebound, but margin pressures continue to weigh significantly.
   Raymond James Cuts Price Target On AngioDynamics  2022/07/13 18:51:15 Benzinga
Raymond James lowered the price target on AngioDynamics Inc (NASDAQ: ANGO ) to $27 from $32 based on a 3.0x group multiple applied to the C23 revenue estimate. At 2.2x EV/sales, Raymond James believes ANGO is undervalued given its growth profile and expects the multiple to expand with continued execution, supporting the Strong Buy rating. The revenue momentum is real and will carry into F23 (guide of 8-10% growth), the analyst wrote. He views back-order fulfillment as a … Full story available on Benzinga.com
   AngioDynamics: Deflationary Tailwinds From Price Inputs, Yet Lack Of Upside To Capture  2022/07/13 03:39:44 Seeking Alpha
AngioDynamics presents with deflationary tailwinds bought on by a softening in key materials used in its manufacturing process.

calendar